HB 0052
Alternative Names: HB-0052Latest Information Update: 12 Jan 2024
At a glance
- Originator Huabo Biopharm
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Nov 2023 Preclinical trials in Solid tumours in China (Parenteral), before November 2023 (Huabo Biopharma pipeline, November 2023)